Nephros (NEPH) Set to Announce Earnings on Thursday

Nephros (NASDAQ:NEPH) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Nephros to announce earnings of $0.02 per share and revenue of $5.49 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter. The firm had revenue of $6.02 million for the quarter, compared to analyst estimates of $4.99 million. Nephros had a net margin of 8.38% and a return on equity of 10.60%. On average, analysts expect Nephros to post $0.15 EPS for the current fiscal year and $0.31 EPS for the next fiscal year.

Nephros Trading Up 2.2%

NEPH opened at $3.24 on Tuesday. Nephros has a 1-year low of $2.66 and a 1-year high of $6.42. The stock has a market capitalization of $35.22 million, a PE ratio of 20.25 and a beta of 1.64. The firm has a 50-day moving average price of $3.89 and a two-hundred day moving average price of $3.68.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Nephros in a research note on Friday. Benchmark reissued a “speculative buy” rating on shares of Nephros in a report on Tuesday, August 18th. Northland Securities started coverage on shares of Nephros in a research report on Friday, July 17th. They issued a “market perform” rating and a $4.00 price objective for the company. Finally, Zacks Research upgraded shares of Nephros to a “hold” rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Nephros presently has an average rating of “Hold” and an average price target of $4.00.

Nephros Company Profile

Nephros, Inc is a medical device company that develops and sells filtration products designed to improve water quality and reduce the risk of waterborne contamination. Its technologies are based primarily on ultrafiltration membranes that remove bacteria, viruses, endotoxins, cysts and other impurities from water.

The company serves the healthcare market with filtration systems for hemodialysis and infection-control applications. Its products are designed for use in hospitals, dialysis centers and other healthcare facilities where purified water is important for patient care and clinical operations.

Nephros also offers commercial water-filtration products for applications such as foodservice, hospitality, commercial buildings and healthcare facilities.